Results 61 to 70 of about 4,675 (181)

Outcome of treatment with trametinib in adults with histiocytic neoplasms in the United Kingdom

British Journal of Haematology, EarlyView.
Trametinib (MEK inhibitor) shows efficacy in refractory and high‐risk adult histiocytic neoplasms. At a median follow‐up of 21.4 months, the clinical response rate was 81% (30/37) and the radiological response was 68% (25/37) (n = 37).
Rodothea Amerikanou, Talha Munir, Kristian Bowles, Christopher McNamara, Nikesh Chavda, Elizabeth Price, Jagdish Adiyodi, Alasdair Coles, Philippa Kelsey, Jeffery Smith, Richard Adams, Hayder Hussein, Rui Zhao, Trung Nguyen, Matthew Collin, Satyen Gohil   +15 more
wiley   +1 more source

Erdheim Chester disease presenting as bilateral breast dimpling and discoloration

Radiology Case Reports
: Erdheim Chester disease is a rare disease characterized by abnormal proliferation of histiocytes. The most commonly affected site is the long bones, while involvement of the breasts is very rare. In patients with breast involvement, a unilateral breast
Christina Oska, DO, Ujas Parikh, MD
doaj   +1 more source

Atypical skeletal involvement in patients with Erdheim–Chester disease: CT imaging findings

Orphanet Journal of Rare Diseases, 2022
Objectives To review retrospectively atypical bone findings from computed tomographic (CT) imaging in patients with Erdheim–Chester disease. Methods All 28 patients with Erdheim–Chester disease (13 men and 15 women; mean age, 45 years; range, 7–63 years)
Zaizhu Zhang, Wei Yu, Wenmin Guan, Qiang Lin, Ali Guermazi   +4 more
doaj   +1 more source

Glomeruloid haemangioma in Erdheim–Chester disease: An atypical skin manifestation associated with elevated vascular endothelial growth factor‐A levels

British Journal of Haematology, EarlyView.
Glomeruloid haemangiomas and extensive angiomas occurred in a small subset of Erdheim–Chester disease patients, all showing markedly elevated vascular endothelial growth factor‐A (VEGF‐A) levels despite the absence of POEMS (polyneuropathy, organomegaly, M‐spike, and skin disease) syndrome.
Jerome Razanamahery, Matthias Papo, Francesco Pegoraro, Felix Blaison, Paul Legendre, Valentin Carado, Martin Caretti, Aubriot Lorton Marie Helene, Jean‐Francois Emile, Augusto Vaglio, Julien Haroche   +10 more
wiley   +1 more source

Doença de Erdheim-Chester: relato de caso

, 2021
A doença de Erdheim-Chester é uma rara histiocitose de células não-Langerhans, primeiramente descrita por Jakob Erdheim e William Chester em 1930 de etiologia desconhecida.
Giongo, Aline Alencar, Santos, Tercia Jovino Neves, Campos, Bruno Santos Leal, Costa, Felipe D\u27Almeida   +3 more
core   +1 more source

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 274-285, July 2026.
BRAF inhibitors and MEK inhibitors (MEKi) have reshaped the treatment of BRAFV600‐mutant malignancies; however, cutaneous adverse drug reactions (ADRs) remain a frequent and clinically impactful toxicity. Although clinical trials provide insight into their safety profiles, real‐world data on dermatologic ADRs are limited.
Natalia Sauer, Piotr Giedziun, Jacek Calik, Anna Wiela‐Hojeńska   +3 more
wiley   +1 more source

Pulmonary involvement in Erdheim-Chester disease

, 2017
Erdheim–Chester disease is a disseminated non-Langerhans’ cell histiocytosis involving multiple organs with characteristic sclerotic musculoskeletal lesions.
김세규, 장준, 박무석, 김성규, 김영삼, 신동환, 최규옥   +6 more
core   +1 more source

Acute Cardiac Tamponade in a 77-year-old Italian Woman with Erdheim-Chester Disease

European Journal of Case Reports in Internal Medicine, 2016
Erdheim-Chester disease (ECD) is a non-Langerhans’ histiocytosis and a very rare multisystemic disease of unknown aetiology, with skeletal involvement of the long bones and in more than 50% of cases with extraskeletal involvement.
Maria Kyriakopoulou, Guy Decaux, Mike El Mourad, Ruben Casado Arroyo   +3 more
doaj   +1 more source

Cardiac MRI Imaging Features of Erdheim–Chester Disease: A Case Review [PDF]

Erdheim–Chester disease (ECD) is a disease of non-Langerhans cell histiocyte multisystemic proliferation. The pathogenesis is related to accumulation of histiocytes across the body, leading to multiple organ failure, and thus necessitating an early ...
Chris Schettino, Aher, Aman, Schettino, Chris, Priya, Sarv, Aman Aher, Sarv Priya, Pritish Aher, Aher, Pritish   +7 more
core   +1 more source

La tamponnade, un mode révélateur de la maladie d’Erdheim-Chester

Journal de la Faculté de Médecine d'Oran, 2022
La maladie d’Erdheim-Chester est une maladie rare. C’est une histiocytose non langerhansienne qui affecte de nombreux organes avec des localisations osseuses, rétro péritonéales, pulmonaires, cardiovasculaires, neurologiques et orbitaires.
Dalila Ahnou, Achour Zahraoui, Mustapha Boubrit   +2 more
doaj